Which way would you prefer to die -- from lung cancer or a heart attack?
Those are basically the choices that users of Pfizer's
In fairness, it doesn't appear that everyone is at risk for heart attacks -- just those who already have cardiovascular disease. The warning is based on a trial in patients with cardiovascular disease where heart attacks were seen more frequently than with placebo treatments. Pfizer is combining its data from previous clinical trials to determine whether the increase holds up in a larger population.
U.S. sales of Chantix peaked at just over $700 million in 2007, its first full year on the market. But warnings of potential suicide risks caused sales to come crashing down to just $330 million last year. Sales outside the United States have helped mute the drop somewhat.
I wouldn't go out and buy cigarette makers such as Altria
Plus, there's GlaxoSmithKline's
If worse comes to worse, doctors will suggest that patients quit the old-fashioned way: sheer willpower. The side effects -- stress and the like -- might not be so great, but death isn't usually among the risks.
Market dips giving you chest pains? Watch this before the market crashes.
Fool contributor Brian Orelli holds no position in any company mentioned. See his holdings and a short bio. The Motley Fool owns shares of Altria Group and GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy wonders why a few people die of E. coli and everyone stops eating vegetables, but thousands die from smoking and few quit.